En Face Doppler Optical Coherence Tomography Measurement of Total Retinal Blood Flow in Diabetic Retinopathy and Diabetic Macular Edema

Abstract

to the New England Eye Center) from Carl Zeiss Meditec and Optovue and serving as a consultant to Regeneron and Genentech. Dr Baumal reports serving as a speaker for Allergan and Genetech, as well as having received compensations from Optovue. Dr Duker reports receiving grants from Carl Zeiss Meditec and Optovue while also serving as a consultant to Carl Zeiss Meditec and Optovue. Dr Duker also reports serving as a consultant to Allergan, Aura Biosciences, Lumenis, Omeros, Santen, Thrombogenics, and Ocudyne; being a stock holder in Hemera Biosciences and Ophthotech; and being on the board of directors of Eleven Biotherapeutics and pSivida Corporation. Dr Fujimoto reports having a personal financial interest in Optovue and also receiving royalties from a patent owned by the Massachusetts Institute of Technology and licensed to Optovue. Dr Fujimoto and Mr Moult report receiving grants from the National Institutes of Health and the Air Force Office of Scientific Research during the conduct of the study. Dr Choi reports receiving grants from the National Institutes of Health during the conduct of the study. No other disclosures are reported.

Optical Coherence Tomography Angiography

“…Studies on patients with diabetic retinopathy show slow and turbulent flow in areas of microaneurysms and vascular pruning, compared to the speed of flow in similar sized vessels without these alterations (Ishibazawa et al, 2016). Moreover, OCT based Doppler techniques suggest a reduction in total retinal blood flow in patients with diabetic macular edema, which is consistent with the extensive peripheral non-perfusion that is often seen on wide field imaging in these patients (Lee et al, 2017;Sadda et al, 2017a).…”

Age-Related Decline of Retinal Oxygen Extraction in Healthy Subjects

“…11,12 Several solutions were proposed to quantify total retinal blood flow (Q) based on Doppler optical coherence tomography (OCT). [13][14][15][16][17][18][19] Recently, a prototype instrument from a commercial company was introduced and good reproducibility was reported. 20 We have developed a technique based on a two-beam approach 15,[21][22][23] that has been validated against invasive microsphere technology in nonhuman primates.…”

The influence of insulin therapy on measurements of optical coherence tomography parameters in diabetic patients without retinopathy

“…We also discovered that the PVD of the using group was lower than that of the without group, although it was a minimal difference. Previous studies reported a 1 0 decrease in pulsatile ocular blood flow was observed in the early stage of observable DR, and a lower PVD was related to the development and progression of DR. [33][34][35] A prior study reported that insulin could induce vascular endothelial production of nitric oxide, which leads to capillary recruitment, vasodilation, and increased blood flow. 36 However, our study demonstrated that insulin use could decrease the ocular PVD.…”